|1.||Wolchok, Jedd D: 56 articles (10/2015 - 01/2008)|
|2.||Hodi, F Stephen: 38 articles (10/2015 - 09/2008)|
|3.||Maio, Michele: 28 articles (07/2015 - 08/2009)|
|4.||Robert, Caroline: 26 articles (08/2015 - 08/2010)|
|5.||Ascierto, Paolo A: 25 articles (12/2015 - 01/2011)|
|6.||Weber, Jeffrey S: 25 articles (06/2015 - 11/2008)|
|7.||Postow, Michael A: 21 articles (01/2016 - 03/2012)|
|8.||Hamid, Omid: 20 articles (08/2015 - 12/2007)|
|9.||Schadendorf, Dirk: 17 articles (12/2015 - 01/2010)|
|10.||Hoos, Axel: 15 articles (09/2015 - 09/2008)|
|1.||Melanoma (Melanoma, Malignant)
05/01/2015 - "The inhibitory anti-CTLA-4 antibody, ipilimumab, dramatically improved survival in a subgroup of metastatic melanoma patients. "
01/01/2012 - "The demonstration of improved survival with the anti-CTLA4 antibody ipilimumab and the BRAF inhibitor vemurafenib in patients with metastatic melanoma is arguably the most significant advance in the treatment for these patients in the last 30 years. "
01/01/2014 - "Ipilimumab has been shown to improve overall survival in patients with metastatic melanoma; however, complete responses (CRs) are uncommon. "
12/01/2012 - "Outstanding issues include the role of ipilimumab in the adjuvant treatment of patients who are at high risk for relapse, and the optimal treatment sequence for patients with BRAFV600 mutant melanoma, as small-molecule BRAF inhibitors have also been shown to improve the survival for this subgroup of patients."
02/01/2011 - "In patients with metastatic melanoma, ipilimumab increases survival time and induces complete remission in some patients. "
12/01/2012 - "Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. "
07/01/2012 - "Analysis of pre-treatment tumors indicated that patients with high baseline expression levels of immune-related genes were more likely to respond favorably to ipilimumab. "
01/01/2013 - "Besides the conventional patterns of response and stable disease as defined by standard Response Evaluation Criteria in Solid Tumors criteria, in subsets of patients, ipilimumab has shown patterns of delayed clinical activity which were associated with an improved overall survival. "
06/01/2015 - "These results demonstrated that ipilimumab induces an effective anti-tumor immune response persisting after the completion of treatment, and suggested a potential remission in a subset of patients. "
08/01/2015 - "All English-language clinical trials assessing the safety and efficacy of ipilimumab, nivolumab, and pembrolizumab in cancer were considered. "
|3.||Neoplasm Metastasis (Metastasis)
03/01/2015 - "CONCLUSIONS In this series, patients who underwent resection of brain metastases in temporal proximity to receiving ipilimumab had qualitatively improved performance status following surgery in most cases. "
01/01/2014 - "Ipilimumab may be effective in a few patients with central nervous system metastasis. "
01/01/2014 - "However, there is a lack of data on the efficacy of ipilimumab in patients with brain metastases. "
06/01/2013 - "In this retrospective study, administration of ipilimumab neither increased toxicity nor improved intracerebral disease control in patients with limited brain metastases who received SRS."
01/01/2014 - "Several groups not included in previous studies, including patients with previously treated brain metastases, Eastern Cooperative Oncology Group PS 2 to 3, or previous ipilimumab treatment had benefitted from vemurafenib similar to the overall population. "
|4.||Prostatic Neoplasms (Prostate Cancer)
02/01/2013 - "This article reviews the molecular basis, preclinical and clinical evidence on the safety and efficacy of ipilimumab in prostate cancer. "
04/01/2013 - "Ipilimumab has been studied in seven phase 1 and 2 clinical trials that evaluated various doses, schedules, and combinations across the spectrum of patients with advanced prostate cancer. "
02/01/2013 - "A number of preliminary clinical studies suggest the potential therapeutic utility of immune checkpoint inhibitors such as ipilimumab in prostate cancer. "
01/01/2013 - "The immune checkpoint inhibitor ipilimumab is also stirring considerable interest, with two phase III trials ongoing in prostate cancer. "
01/01/2013 - "As a single agent, ipilimumab is also being clinically evaluated in advanced (metastatic, castrate-resistant) prostate cancer and two randomized, placebo-controlled Phase III studies have recently completed accrual. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2013 - "An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer."
07/01/2012 - "Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer."
03/01/2012 - "This review details the potential of ipilimumab in the management of non-small cell lung cancer (NSCLC). "
03/01/2012 - "Ipilimumab: its potential in non-small cell lung cancer."
01/01/2014 - "Ipilimumab in combination with chemotherapy has exhibited encouraging results in small-cell and non-small-cell lung cancer alike. "
|1.||cytotoxic T-lymphocyte antigen 4